Article

Glistening-free, hydrophobic acrylic IOL debuts

A new glistening-free, hydrophobic acrylic IOL (enVista, Bausch + Lomb) debuted at the annual meeting of the European Society of Cataract and Refractive Surgeons here.

Vienna, Austria-A new glistening-free, hydrophobic acrylic IOL (enVista, Bausch + Lomb) debuted at the annual meeting of the European Society of Cataract and Refractive Surgeons here.

The lens’ aspheric, aberration-free technology (Advanced Optics, Bausch + Lomb) is designed to deliver enhanced contrast sensitivity and better vision quality, and its 360° square-edge barrier design aims to provide an effective optic-haptic junction to minimize posterior capsular opacification.

“We are proud to innovate the hydrophobic lens category with an IOL that provides a high quality of vision and addresses the common issue of glistenings,” said Robert Grant, chief executive officer and president of global surgical business for Bausch + Lomb. “It was important that we deliver an advanced hydrophobic lens that surgeons and patients can count on now and over the long term, and data [show] that we have achieved that.”

The hydrophobic lens has received CE mark approval in the European Union. Additional approvals are pending worldwide, according to the company.

For more articles in this issue of

Ophthalmology Times Conference Brief

click here

.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.